FTRE — Fortrea Holdings Inc. stock price, charts and financials

QT86Fortrea Holdings Inc.

Fortrea Holdings Inc. (NASDAQ: FTRE) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
18.70
+0.27+1.49%
OverviewShort InterestFilings
FTREQT86Fortrea Holdings Inc.·NASDAQ
18.70+1.49%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
AUPH-2.24%$15.49MESO+4.92%$16.73ZBIO-0.80%$32.17GHRS-1.85%$29.71TSHA-0.67%$6.52STOK-1.01%$32.38ABCL+32.25%$9.16VRDN-1.42%$23.26
Snapshot
Index-P/E-EPS (ttm)-0.93Insider Own3.32%Shs Outstand95.10MPerf Week-3.86%
Market Cap1.75BForward P/E17.32EPS next Y1.06Insider Trans-7.78%Shs Float94.21MPerf Month4.30%
Enterprise Value1.66BPEG-EPS next Q0.25Inst Own-Short Float10.89%Perf Quarter18.37%
Income-85.88MP/S0.65EPS this Y190.39%Inst Trans-Short Ratio7.18Perf Half Y33.55%
Sales2.68BP/B3.31EPS next Y26.60%ROA-3.14%Short Interest10.26MPerf YTD6.84%
Book/sh-P/C9.53EPS next 5Y25.32%ROE-15.53%52W High21.71 -13.84%Perf Year180.09%
Cash/sh-P/FCF11.64EPS past 3/5Y-ROIC0.62%52W Low6.16 203.62%Perf 3Y-38.57%
Dividend Est.-EV/EBITDA20.50Sales past 3/5Y-1.36% 1.08%Gross Margin17.11%Volatility8.07% 5.68%Perf 5Y-
Dividend TTM-EV/Sales0.62EPS Y/Y TTM74.66%Oper. Margin0.41%ATR (14)1.23Perf 10Y-
Dividend Ex-Date-Quick Ratio0.96Sales Y/Y TTM-0.70%Profit Margin-3.18%RSI (14)51.17Recom2.67
Dividend Gr. 3/5Y-Current Ratio0.96EPS Q/Q21.05%SMA20-1.25%Beta2.11Target Price20.00
Payout0.00%Debt/Eq0.15Sales Q/Q-4.51%SMA505.67%Rel Volume0.68Prev Close18.43
Employees14,000LT Debt/Eq1.95EarningsNov 04SMA20033.01%Avg Volume1.45MPrice18.70
IPO DateJun 20, 2023Option/ShortYes / YesEPS/Sales Surpr.27.47% 4.73%Net Debt/EBITDA-1.09Volume989,727Change1.49%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-30-26ReiteratedDeutsche BankHold$18 → $20
Jul-30-26ReiteratedRobert W. Baird$21 → $23
Jul-30-26ReiteratedBarclaysEqual Weight$18 → $22
Jul-13-26ReiteratedMizuhoNeutral$15 → $16
Jun-24-26ReiteratedBarclaysEqual Weight$16 → $18
May-07-26ReiteratedDeutsche BankHold$11 → $14
May-06-26ReiteratedTruist FinancialBuy$16 → $19
May-06-26ReiteratedRobert W. Baird$15 → $20
May-06-26ReiteratedBarclaysEqual Weight$11 → $16
Apr-14-26ReiteratedBarclaysEqual Weight$15 → $11
Latest News
Aug-04-26
Aug-04-2612:33PM
TD Cowen Maintains Buy on Fortrea Holdings, Raises Price Target to $23Benzinga
Jul-31-26
Jul-31-2604:11PM
Citigroup Maintains Buy on Fortrea Holdings, Raises Price Target to $22Benzinga
01:01PM
Fortrea Holdings Inc. (FTRE) Upgraded to Strong Buy: Here's What You Should Knowzacks.com
12:40PM
FTRE vs. ARGX: Which Stock Is the Better Value Option?zacks.com
11:02AM
Best Momentum Stock to Buy for July 31stzacks.com
09:55AM
Fortrea Holdings Inc. (FTRE) Is Attractively Priced Despite Fast-paced Momentumzacks.com
Jul-29-26
Jul-29-2605:13PM
Fortrea Holdings Inc. (FTRE) Q2 2026 Earnings Call Transcriptseekingalpha.com
11:08AM
Fortrea Q2 Earnings Call Highlightsmarketbeat.com
09:26AM
Fortrea Holdings Inc. (FTRE) Surpasses Q2 Earnings and Revenue Estimateszacks.com
06:30AM
Fortrea Reports Second Quarter 2026 Resultsglobenewswire.com
Jul-24-26
Jul-24-2605:00AM
Top Healthcare Stocks Beyond The Market Rotation Averaging 128% Forward EPS GrowthSeekingAlpha
Jul-23-26
Jul-23-2607:00AM
Kaskela Law Firm Announces Investigation of Fortrea Holdings Inc. (FTRE) and Encourages Long-Term FTRE Shareholders with Investment Losses to Contact the Firmbusinesswire.com
Jul-13-26
Jul-13-2609:00AM
Fortrea Announces Date for Second Quarter 2026 Financial Results and Conference Callglobenewswire.com
08:14AM
Mizuho Maintains Neutral on Fortrea Holdings, Raises Price Target to $16Benzinga
Jul-09-26
Jul-09-2602:06PM
Stocks Look Shaky, But This Sector is Booming (Biotech)zacks.com
Company

Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
Total Revenue2,6772,7232,696————
Cost of Goods Sold Incl. D&A2,2192,2982,162————
Gross Profit458426534————
Selling, General and Administrative Excl. Other413456561————
Research and Development
000————
Other Operating Expense340135————
Operating Income11-31-162————
Interest Expense8491124————
Unusual Expense
———————
Non-Operating Income (Expense)-5-86111————
Net Income Before Taxes-78-983-275————
Income Taxes73-3————
Consolidated Net Income-85-986-328————
Net Income From Continuing Operations-85-986-271————
Net Income-85-986-328————
EPS (Recurring)-0.93-10.81-3.67————
EPS (Basic, Before Extraordinaries)-0.93-10.81-3.67————
EPS (Diluted)-0.93-10.81-3.67————
EBITDA81-814-64————
Other After Tax Adjustments
———————
Stock Option Compensation Expense
———————
Price To Earnings Ratio
———————
Price To Sales Ratio0.660.580.62————
Gross Margin17.1115.6419.81————
Operating Margin0.41-1.14-6.01————
Net Margin-3.18-36.21-12.17————
Shares Outstanding949190————
Market Capitalization1,7581,5701,678————
Operating Lease Expense
———————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$23.19$17.80$12.41$7.03$1.64● Close Price0.00M1.03M2.06M3.09M4.11MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Thakral AnshulChief Executive OfficerAug 06 '26Sale18.11111,8572,026,284204,940Aug 07
Thakral AnshulChief Executive OfficerAug 05 '26Sale19.1699,8691,913,112316,797Aug 06
Thakral AnshulChief Executive OfficerAug 04 '26Option Exercise0.00416,6660416,666Aug 06
SANDERS MACHELLEDirectorAug 03 '26Sale18.019,700174,69736,399Aug 05
Smith David RossDirectorJul 20 '26Option Exercise0.006,598036,715Jul 27
Morais Mark A.Chief Operating OfficerJun 10 '26Sale16.824,67478,61771,365Jun 12
Ray AmritDirectorJun 10 '26Option Exercise0.0038,817052,453Jun 12
Russell Erin LDirectorJun 10 '26Option Exercise0.0038,817072,617Jun 12
SANDERS MACHELLEDirectorJun 10 '26Option Exercise0.0038,817046,099Jun 12
Smith David RossDirectorJun 10 '26Option Exercise0.0038,817048,361Jun 12
Pesicka Edward ADirectorJun 10 '26Option Exercise0.0038,817052,453Jun 12
Parks RobertChief Accounting OfficerMay 18 '26Sale13.442,00026,88020,389May 20
NEUPERT PETER MDirectorMay 14 '26Option Exercise0.00148,5360246,668May 18
Russell Erin LDirectorMar 20 '26Option Exercise0.0023,946033,800Mar 24
Mcconnell Jill G.Chief Financial OfficerMar 16 '26Sale9.221,80416,63372,276Mar 17
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.